Trials / Completed
CompletedNCT01459939
A Double-blind, Randomized, Parallel Group, Fase III Comparative Study With Rose Hip Powder Powder and Placebo Given to Patients With Mild to Moderate Osteoarthritis in the Knee or/and Hip
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Hyben Vital ApS · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Accepted
Summary
The trial is an investigator-initiated, double-blind, randomized, placebo-controlled phase III study. After the patient has receiving information about the study and after given written informed consent, the patient will be screened. All patients are randomized to receive standardized rose hip powder or matching placebo for 3 weeks followed by half the dose standardized rose hip (or placebo) for the remaining 12 weeks of the study. The patient's medical history and demographic information will be recorded. The patient will then be asked questions in accordance to the study questionnaires, and they will also be asked to complete questionnaires regarding quality of life - and finally they be instructed on how to complete the diary. Investigator or study nurse will take telephone contact with the subject after 3 and 6 weeks of treatment, subjects will be asked about how things are going and to remember to take the capsules and whether they have completed the diary. The contact taken after 6 weeks by phone is mainly to guide the subject on how complete the questionnaires including VAS scales. The last patient visit will take place after 12 weeks. Any side effects will be reported to and reviewed with HybenVital ApS in collaboration with medical experts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Rose-hip powder capsules | 5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks |
| DIETARY_SUPPLEMENT | Placebo | 5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2012-02-01
- Completion
- 2012-05-01
- First posted
- 2011-10-26
- Last updated
- 2012-06-06
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT01459939. Inclusion in this directory is not an endorsement.